Novavax, Inc. (NVAX) — closed signal from March 7, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 5, 2026.
Predicted vs. what happened
What happened
Reached 74% of the predicted growth at its peak, without hitting the target.
The thesis — published March 7, 2026
Novavax looks more promising for the next few months because recent events changed the company story from just surviving to actually executing its plans. They reported an unexpected profit, sales rose, and a licensing deal with Pfizer makes their path to selling products more believable. The stock is still jumpy, so treat this as a careful re-rating trade instead of chasing a fast run.
Primary drivers
- An unexpected profit made the company look more reliable to investors
- A deal with Pfizer gives clearer ways for the company to make money
- The stock's recent price pattern supports buying on small dips
- Company is focusing on selling products instead of just surviving
How it played out
NVAX: thesis partly played out but target was missed
Lyra published NVAX at $9.98 on March 7, 2026, with expected growth of 22%. The thesis pointed to an unexpected profit, higher sales, a Pfizer licensing deal, a better path to selling products, and a price pattern that supported buying small dips.
Inside the window, the stock rose but did not reach the $12.18 target. It peaked at $11.61 on May 27, 2026, for a 16.3% gain. It never got there. By June 5, 2026, NVAX ended at $9.49. The thesis partly played out, but the target was missed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.